Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer

Table 1 Comparison of basic data between the two groups

Item		Observation group, n = 46	Control group, n = 46	χ2	P value
Sex	Male	24 (52.17)	25 (54.35)	0.044	0.834
	Female	22 (47.83)	21 (45.65)
Age in yr		58.34 ± 3.28	58.54 ± 3.49	0.283	0.778
Pathological type	Colon cancer	33 (71.74)	31 (67.39)	0.205	0.650
	Rectal cancer	13 (28.26)	15 (32.61)
Differentiation degree	Low differentiation	41 (89.13)	37 (80.43)	0.494	0.482
	Moderate to high differentiation	5 (10.87)	7 (15.22)
TNM stage	Stage III	34 (73.91)	32 (69.57)	0.215	0.643
	Stage IV	12 (26.09)	14 (30.43)
Distant metastasis	Hepatic metastasis	2 (4.35)	1 (2.17)	0.000	1.0001
	Pulmonary metastasis	1 (2.17)	0 (0.00)	0.000	1.0001
	Pelvic metastasis	1 (2.17)	1 (2.17)	0.511	0.4751

¹The use of continuity correction, which is applied in χ²tests when the expected frequency is less than or equal to 5 to perform a continuity-corrected test. Data are n (%) or mean ± SD.